| 赵晓红 周仲昊 陆时运 王晨 王智.减低剂量去甲氧柔红霉素联合阿糖胞苷方案治疗老年急性髓细胞
白血病的临床研究[J].,2014,14(35):6938-6942 |
| 减低剂量去甲氧柔红霉素联合阿糖胞苷方案治疗老年急性髓细胞
白血病的临床研究 |
| The Clinical Study of Dose-reduced Idarubicin and Cytarabine as TherapeuticRegimen in Elderly Patients with Acute Myeloid Leukemia |
| |
| DOI： |
| 中文关键词: 减低剂量 去甲柔红霉素 老年患者 急性髓细胞白血病 |
| 英文关键词: Reduced dose Idarubicin Elderly patients Acute myeloid leukemia |
| 基金项目: |
|
| 摘要点击次数: 702 |
| 全文下载次数: 825 |
| 中文摘要: |
| 目 的： 探讨减低剂量去甲柔红霉素联合阿糖胞苷(IA)方案治疗 老年急性髓细胞白血病(AML)患者的疗效。 方法： 收集我院老
年急性髓细胞白血病患者 62 例， 随机分成减低剂量 IA 治疗组和标准剂量 IA 对照组，两组均实施 3+7 治疗方案。 治疗 2 个疗程，
比较两组不良反应和临床疗效。 结果： 减低剂 量 IA 治疗 组总 CR 率和 CCR 率分别为 75.0%和 66.7%； 标准剂 量 IA 对照组总 CR
率和 CCR 率分别 为 50.0%和 33.3%。 减低剂 量 IA 治疗组总生存期 25+ 月 较标准剂量 IA 对照组生存期 23+ 月 延长。 结论： 对于老
年急性髓细胞白血病患者， 减低剂量 IA 治疗方案的 CR 率和 CCR 率与 标准剂量 IA 治疗方案相比具有明显疗效优势。 |
| 英文摘要: |
| Objective:To investigate the curative effect of dose- reduced idarubicin and cytarabine (IA) as therapeutic regimen in
elderly patients with acute myeloid leukemia (AML).Methods:62 cases of elderly patients with acute myeloid leukemia were collected
and randomly divided into reduced dose IA therapy group and the standard dose IA control group, and both of the two groups received
3+7 treatment. The clinical efficacy and adverse reactions of the two groups were compared after two courses of treatment.Results:The
total CR rate and CCR rate of reduced dose IA therapy group were 75% and 66.7%, and in standard dose IA control group, they were
50% and 33.3%, respectively. The overall survival of therapy group (25+ month) had extended when compared with that of the control
group (23+ months).Conclusion:Reduced dose IA astherapeutic regimen in elderly patients with acute myeloid leukemia has obvious advantage in curative effect when compared with the standard dose IA treament. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
